Metropolitan Life Insurance Company (MetLife)’s Carisma Therapeutics CARM Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,470	Closed	-$6.22K	–	2353
2023 Q3	$6.22K	Hold	1,470	–	–	﹤0.01%	2377
2023 Q2	$12.9K	Buy	+1,470	New	+$8K	﹤0.01%	2164
2021 Q3	–	Sell	-2,506	Closed	-$232K	–	2843
2021 Q2	$232K	Buy	+2,506	New	+$160K	﹤0.01%	2039

Other funds holding CARM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TOTUOP

Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CARM Position: Q4 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Carisma Therapeutics (CARM) in Q4 2023, closing a stake of 1,470 shares — an estimated $6.22K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CARM in Q2 2021 and held it in 3 quarters. The position peaked at $232K in Q2 2021. 50 funds tracked by Wall St. Rank hold CARM as of Q4 2023.

Metropolitan Life Insurance Company (MetLife) reported no remaining Carisma Therapeutics position as of Q4 2023 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 1,470 Carisma Therapeutics shares in Q4 2023, an estimated $6.22K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Carisma Therapeutics in Q2 2021 and held it in 3 quarters.
Metropolitan Life Insurance Company (MetLife)'s Carisma Therapeutics position peaked at $232K in Q2 2021.
50 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2023, filed 14 Feb 2024.